Transcenta Holding Limited (6628.HK)
| Previous close | 1.850 |
| Open | 1.850 |
| Bid | 1.810 x N/A |
| Ask | 1.840 x N/A |
| Day's range | 1.810 - 1.850 |
| 52-week range | 1.170 - 5.720 |
| Volume | |
| Avg. volume | 62,000 |
| Market cap | 801.357M |
| Beta (5Y monthly) | -0.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.250 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.37 |
PR NewswireTranscenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilent Technologies, announce a collaboration to develop a Claudin18.2 (CLDN18.2) companion diagnostic to support TranStar301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line treatment in patients with CLDN18
- PR Newswire
Transcenta Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the preclinical anti-tumor efficacy and safety results of [177Lu]Lu-TST001 have been published on European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI). In this preclinical studies, [177Lu]Lu-TST001 demonstrated significant antitumor efficacy with ac
- PR Newswire
Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical-stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented updated efficacy data from the expansion cohort of the TranStar102 of Osemitamab (TST001) plus CAPOX chemotherapy study as the first-line treatment of advanced G/GEJ Cancer at the ESMO Congress 2023 in Madrid, Spain. The updated data continued to
